H-1152

CHF 96.00
In stock
SYN-1221-M0011 mgCHF 96.00
SYN-1221-M0055 mgCHF 227.00
SYN-1221-M01010 mgCHF 347.00
SYN-1221-M05050 mgCHF 1'185.00
SYN-1221-M100100 mgCHF 1'903.00
 
More Information
Product Details
Synonyms (S)-4-Methyl-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline dihydrochloride; H1152
Product Type Chemical
Properties
Formula C16H21N3O2S . 2HCl
MW 319.4 . 72.9
CAS 871543-07-6
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: ROCK | Kinase Group: AGC | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key BFOPDSJOLUQULZ-GXKRWWSZSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
H-1152 is a potent, specific, ATP-competitive and cell permeable ROCK inhibitor, with an IC50 of 12nM for ROCKII. H-1152 poorly inhibits PKA, PKC and myosin light chain kinase. Rho kinase (ROCK) activated by GTP-linked Rho phosphorylates targets that are involved in cytoskeletal remodelling, smooth muscle contraction and neuronal development.
Product References
  1. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway: Y. Sasaki, et al.; Pharmacol. Ther. 93, 225 (2002)
  2. Development of specific Rho-kinase inhibitors and their clinical application: M. Tamura, et al.; Biochim. Biophys. Acta 1754, 245 (2005)
  3. Proerectile effects of the rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis: C.E. Teixeira, et al.; J. Pharmacol. Exp. Ther. 315, 155 (2005)
  4. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse: H.L. Wang, et al.; Neuropharmacol. 70, 1 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.